Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 6,931 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 6,931 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $45.22, for a total value of $313,419.82. Following the sale, the director now owns 337,752 shares in the company, valued at $15,273,145.44. The trade was a 2.01 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Pro-Dex Stock Performance

NASDAQ:PDEX traded down $2.67 during mid-day trading on Wednesday, hitting $41.65. The stock had a trading volume of 26,575 shares, compared to its average volume of 28,329. Pro-Dex, Inc. has a twelve month low of $16.18 and a twelve month high of $59.60. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The stock has a market cap of $135.78 million, a price-to-earnings ratio of 27.05 and a beta of 0.56. The company's 50 day simple moving average is $48.09 and its 200 day simple moving average is $33.44.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PDEX. StockNews.com raised Pro-Dex from a "buy" rating to a "strong-buy" rating in a research report on Saturday, December 14th. Ascendiant Capital Markets upped their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, November 11th.

Institutional Trading of Pro-Dex

A number of hedge funds have recently made changes to their positions in PDEX. FMR LLC increased its holdings in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after acquiring an additional 1,028 shares during the last quarter. Renaissance Technologies LLC boosted its position in Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after purchasing an additional 900 shares during the period. Bard Associates Inc. increased its holdings in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. Ritholtz Wealth Management bought a new position in shares of Pro-Dex in the fourth quarter valued at about $572,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after buying an additional 529 shares during the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.